The technology that Valor developed, Neucrylate^TM, is a liquid that is injected into a cerebral aneurysm through a micro-catheter placed from the femoral artery. When Neucrylate comes in contact with blood, the liquid changes into a solid material similar to a sponge. The surgical procedure for injecting Neucrylate will take less time, yet offers a more complete filling of the aneurysm as compared to coiling. Dr. Charles Kerber, Professor of Neuroradiology, UCSD, San Diego, CA, and Valor Medical founder, stated, “Coiling has been a true advancement in the treatment of cerebral aneurysms. Neucrylate will advance the treatment even further by decreasing the surgical time and reducing the risks and failures associated with coiling.”

A cerebral aneurysm is a balloon-like swelling of the wall of a blood vessel in the brain. This weakening in the wall often leads to rupture, bleeding and death. Cerebral aneurysms are more common in people over 65, they may be found in as high as 5% of the population. Smoking and hypertension appear to markedly increase the chance that one will develop a cerebral aneurysm. Approximately 30,000 people in the United States are diagnosed each year with a cerebral aneurysm. However, there are an estimated 4.5 million individuals in the U.S. that have silent, undiagnosed cerebral aneurysms.